Proxy endpoints — bridging clinical trials and real world data
Having disease severity over time for a patient is important to further disease understanding and management. Our results open the door to more use cases in the space of RA and AD such as treatment effect estimates or prognostic scoring on RWD. Our framework may be extended beyond RA and AD to other diseases where the severity score is not well measured in electronic health records.
Authors
- Brandon Rufino (ORCID: https://orcid.org/0000-0003-0253-7496)
- Flavio Dormont (ORCID: https://orcid.org/0000-0001-7309-1853)
- Ramón Díaz Hernández (ORCID: https://orcid.org/0000-0003-1338-9046)
- Ziv Bar‐Joseph (ORCID: https://orcid.org/0000-0003-3430-6051)
- Kathleen P. Moriarty
- Maxim Kryukov
- Macarena Villamea
- Ingrid O'Dwyer
- Ohn Chow
Institutions
- Sanofi (France) (FR)
- Sanofi (Spain) (ES)
Publication Details
- Journal
- Journal of Biomedical Informatics
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1016/j.jbi.2024.104723
- Citations
- 3
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 3.39
Funders
- Sanofi